Format

Send to

Choose Destination
Rheumatology (Oxford). 2016 Jan;55(1):103-8. doi: 10.1093/rheumatology/kev300. Epub 2015 Aug 28.

Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease.

Author information

1
Rheumatology Unit, Oslo University Hospital Rikshospitalet, ragunnar@gmail.com.
2
Department of Immunology and Transfusion Medicine, Oslo University Hospital.
3
Department of Radiology, Oslo University Hospital Rikshospitalet.
4
Institute of Clinical Medicine, University of Oslo and.
5
Institute of Clinical Medicine, University of Oslo and Department of Respiratory Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
6
Rheumatology Unit, Oslo University Hospital Rikshospitalet.
7
Rheumatology Unit, Oslo University Hospital Rikshospitalet, Institute of Clinical Medicine, University of Oslo and.

Abstract

OBJECTIVE:

MCTD is a chronic, immune-mediated disorder defined by the combined presence of serum anti-RNP antibodies and distinct clinical features, including progressive lung fibrosis. The aim of the study was to evaluate the potential impact of anti-SSA (i.e. Ro52 and Ro60) and anti-SSB autoantibodies as markers for disease outcomes in MCTD.

METHODS:

Stored serum samples from 113 patients included in the cross-sectional, nationwide Norwegian MCTD cohort were screened for the presence of anti-Ro52, anti-Ro60 and anti-SSB by a commercial line immunoassay. Correlation analyses were carried out with clinical parameters, including quantitative lung fibrosis scores by high-resolution CT. Lung fibrosis was defined by reticular pattern changes according to the Fleischner Society CT criteria for interstitial lung disease.

RESULTS:

Anti-Ro52 antibodies were present in 29%, anti-Ro60 in 19% and anti-SSB in 6% of the MCTD sera. High-resolution CT scoring identified lung fibrosis in 38 of 113 (34%) MCTD patients. Anti-Ro52 antibodies were detected in 50% (19 of 38) of the MCTD patients with lung fibrosis and in 19% (14 of 75) without lung fibrosis (P < 0.001). The odds ratio for the presence of anti-Ro52 antibodies in lung fibrosis was 4.4 (95% CI 1.8, 10.3). Anti-Ro52 antibodies were equally frequent in patients with mild to moderate (eight of 17; 44%) and severe fibrosis (11 of 21; 52%). Anti-Ro52 was not associated with any of the other clinical parameters assessed, nor was anti-Ro60 or anti-SSB.

CONCLUSION:

Our cross-sectional data suggest that anti-Ro52 antibodies may serve as a potential marker for lung fibrosis in MCTD.

KEYWORDS:

SSB antigen; Sjögren’s syndrome; anti-La; anti-Ro; anti-SSA/Ro52; anti-SSA/Ro60; interstitial pulmonary fibrosis; lung diseases; mixed connective tissue disease; scleroderma systemic

PMID:
26320136
DOI:
10.1093/rheumatology/kev300
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for Norwegian BIBSYS system
Loading ...
Support Center